Weekly issue 2026-W41 ·
Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment
Plain language
Tolvaptan makes urine more dilute. Re-analysing the large TEMPO 3:4 trial, researchers asked whether how much urine concentration drops in the first 3 weeks predicts long-term benefit. In non-Japanese participants, a bigger early drop went with better kidney function at 3 years; in the smaller Japanese group, the link was not clear. Either way, tolvaptan slowed kidney growth in both groups. A simple urine test might one day help gauge response.
Clinical note
Post hoc causal mediation analysis of TEMPO 3:4 (3-year RCT). Week-3 change in urine osmolality significantly mediated the tolvaptan effect on month-36 eGFR in non-Japanese participants (ACME 2.4; 95% CI 1.2–3.6; n=948) but not in Japanese participants (ACME −0.3; n=138), where the direct effect on eGFR was significant (ADE 8.4). Direct effect on %TKV change significant in both cohorts (−8.3 and −12.0). Supports early Uosm change as a candidate response biomarker; not validated for individual dose titration or stopping decisions.
Question for your next visit
If I take tolvaptan, would checking my urine concentration early on help us understand whether it is working for me?